Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer's Disease Pathology

Jason D Ulrich; Tien-Phat Huynh; David M Holtzman

doi:10.1016/j.neuron.2015.10.008

Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer's Disease Pathology

Neuron. 2015 Oct 21;88(2):237-9. doi: 10.1016/j.neuron.2015.10.008.

Authors

Jason D Ulrich¹, Tien-Phat Huynh¹, David M Holtzman²

Affiliations

¹ Department of Neurology, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA; The Knight Alzheimer's Disease Research Center, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA.
² Department of Neurology, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA; The Knight Alzheimer's Disease Research Center, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA. Electronic address: holtzman@neuro.wustl.edu.

PMID: 26494271
DOI: 10.1016/j.neuron.2015.10.008

Abstract

Blood-brain barrier disruption is believed to occur in Alzheimer's disease, which could influence the bioavailability of drugs within the brain. However, in this issue of Neuron, Bien-Ly et al. (2015) report no evidence of widespread blood-brain barrier dysfunction.

Publication types

Comment

MeSH terms

Alzheimer Disease / metabolism*
Animals
Antibodies / metabolism*
Antibodies / therapeutic use*
Blood-Brain Barrier / metabolism*
Disease Models, Animal*
Female
Humans
Male

Substances

Antibodies